Keytruda showed a significant survival benefit over Tecentriq and Opdivo in older adults with metastatic NSCLC, with a 33% ...

Opdivo + Yervoy cut cancer progression or death risk by 79% vs. chemo in first-line MSI-H/dMMR colorectal cancer patients. PFS at 12 months was 79% with Opdivo + Yervoy vs. 21% with chemo; median PFS ...

unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), and unresectable or advanced hepatocellular carcinoma (HCC) 1. This dual ...

Bristol Myers Squibb is gunning for newly diagnosed unresectable liver cancer—again—after an immunotherapy setback five years ago. The dual immunotherapy combination of Opdivo and Yervoy showed it can ...

The KEYNOTE-671 trial showed a 71% 36-month overall survival rate with perioperative Keytruda, compared to 64% with placebo. FDA approvals for Keytruda, Imfinzi, and Opdivo in perioperative settings ...

Application based on CheckMate -816, the first Phase 3 trial with an immunotherapy-based combination to demonstrate improved event-free survival and pathologic complete response in this setting If ...

The immunotherapy Opvido and reirradiation resulted in a one-year progression-free survival rate of 61.7% among certain patients with head and neck cancer. Among patients with recurrent head and neck ...

(Reuters) -Bristol Myers Squibb beat Wall Street estimates for third-quarter revenue on Thursday, as strong growth of its cancer immunotherapy and blood thinner Eliquis helped the drugmaker overcome a ...

If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for the first-line treatment of untreated, unresectable or metastatic urothelial carcinoma in ...